Blog
GLP-1 RA prescription trends: January 2019 – September 2026
GLP-1 RAs reached 8.73% of prescriptions in September 2026. Explore the latest trends in tirzepatide, semaglutide, orforglipron, and first-time prescribing.
GLP-1 prescriptions remained elevated three months after Medicare GLP-1 Bridge launch
Understanding the real-world burden of ornithine transcarbamylase deficiency (OTCD): New insights into a rare disease
AMCP Nexus: Early uptake of oral semaglutide for obesity (Wegovy pill)
Truveta Genome Project: The next chapter in Saving Lives with Data
CGM use associated with lower risk of death and cardiovascular events in adults with type 2 diabetes
CGM use in adults with type 2 diabetes on basal insulin was linked to 44% lower risk of death and fewer heart attacks and strokes in…
Learning together is healthcare’s greatest innovation
